1. Medtech Insight
  2. >>Business
  3. >>Deals

Minute Insight: Sema4 To Acquire Genomics Company GeneDx For $623M To Strengthen Clinical Data Platform

 
• By Marion Webb

Genetic testing company Sema4 announced plans to buy GeneDx to strengthen Sema4’s health intelligence and genomic screening offers. The combined company is expected to generate $350m in pro forma 2022 revenue. 

Minute Insight
• Source: Informa/Alamy

Just months after genetic-testing and health-data analytics business Sema4 Holdings Corp. combined with blank-check company CM Life Sciences Inc., it announced plans to acquire OPKO Health’s subsidiary GeneDx, Inc. in a deal valued at $623m. Blank-check companies, or SPACs as they are often called, are formed specifically to find a start-up, buy it and take it public. (Also see "Blank Check Companies’ Hunt For Innovative Medtech Start-Ups To Heat Up Further, Experts Predict" - Medtech Insight, 2 February, 2021.)

Sema4 announced on 18 January plans to buy GeneDx, which it considers a leader in rare disease diagnostic and exome...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

PFA Market Surges As UK NICE Opens Doors And US FDA Approves Boston, J&J Incremental Innovations

 
• By Natasha Barrow

The pulsed-field ablation market is surging, with the UK NHS opening doors and FDA updates for major players. Medtech Insight spoke with Steven Mickelsen, founder of Farapulse (the first clinically approved PFA system), about the sector's growth and his new venture, Field Medical.

Waters’ Purchase Of BD Biosciences & Dx Brings Growth Potential Alongside Trade-Offs

 
• By Marion Webb

Waters Corp. will acquire Becton Dickinson’s Biosciences and Diagnostics business for $17.5bn, doubling its TAM to $40B. Analysts praise the flow cytometry addition but see weaker growth in diagnostics.

Deals Shaping The Medtech And Diagnostics Industries, June 2025

 
• By Medtech Insight Team

An interactive look at medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.

Thena Capital’s New Fund Up And Running With £1M Investment In Plexāā’s Breast Cancer Device

 
• By Natasha Barrow

Thena Capital, the first UK-based early-stage specialist medtech firm, has made its first investment since closing its £50m fund. Medtech Insight spoke with general partner Pamela Walker Geddes to gain insight into Thena Capital’s investment strategy.

More from Business

Deals Shaping The Medtech And Diagnostics Industries, June 2025

 
• By Medtech Insight Team

An interactive look at medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.

HealthAI: ‘Established Regulations Already Exist For Regulating AI In Healthcare Safely’

 
• By Natasha Barrow

Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.

Endo Tools, Fujifilm Partner to Fast-Track Endomina Rollout Across MEA Region

 
• By Shubham Singh

CEO Alexandre Chau told Medtech Insight that the Middle East and Africa presented the ideal mix of market potential, physician training opportunities, and regulatory readiness when the company was considering expansion markets beyond Europe and the US.